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Abstract
Hepatitis C virus infection is a major cause of hepatocellular carcinoma worldwide. Interferon has been the major
antiviral treatment, yielding viral clearance in approximately half of patients. New direct-acting antivirals substantially
improved the cure rate to above 90%. However, access to therapies remains limited due to the high costs and under-
diagnosis of infection in specific subpopulations, e.g., baby boomers, inmates, and injection drug users, and therefore,
hepatocellular carcinoma incidence is predicted to increase in the next decades even in high-resource countries.
Moreover, cancer risk persists even after 10 years of viral cure, and thus a clinical strategy for its monitoring is urgently
needed. Several risk-predictive host factors, e.g., advanced liver fibrosis, older age, accompanying metabolic diseases
such as diabetes, persisting hepatic inflammation, and elevated alpha-fetoprotein, as well as viral factors, e.g., core
protein variants and genotype 3, have been reported. Indeed, a molecular signature in the liver has been associated
with cancer risk even after viral cure. Direct-acting antivirals may affect cancer development and recurrence, which
needs to be determined in further investigation.
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Background
Chronic infection of hepatitis C virus (HCV), estimated to
affect more than 150 million individuals globally, has
proven a major health problem by causing liver cirrhosis
and cancer. Hepatocellular carcinoma (HCC), the major
liver cancer histological type, is the second leading cause
of cancer mortality worldwide [1]. Interferon-based
regimens have been the mainstay of anti-HCV therapy,
yielding HCV cure, or sustained virologic response (SVR),
in approximately 50% of patients [2]. Recently developed
direct-acting antivirals (DAAs), which directly target the
viral protease, polymerase, or non-structural proteins,
have enabled interferon-free anti-HCV therapies with a
revolutionary improvement of SVR rate, approaching or
surpassing 90% [3]. Despite the unprecedentedly high
antiviral efficacy, access to therapy remains limited, at less
than 10% of the total number of HCV-infected individuals,
especially in developing countries, due to the high drug
costs [4, 5]. In addition, the high frequency of unrecognized
HCV infection in the general and specific (e.g., inmates and
homeless) populations, estimated at 50% or above of in-
fected individuals, hampers control of the virus even with
the commercialization of DAAs [5, 6]. With the 3–4 million
newly infected cases each year, it is estimated that the HCV-
associated disease burden will remain high in the next dec-
ade, even in developed countries [7–9].
Wider use of DAAs has revealed several limitations,
including more refractory genotype 1a or 3 virus,
emergence of resistant HCV stains with characteristic
resistance-associated substitutions, and poorer response
in prior non-responders to interferon-based therapies
[10]. These findings warrant further development of alter-
native strategies such as the application of specific DAA
combination therapies to target resistant HCV strains,
host targeting agents/viral entry inhibition, and the
development of diagnostic tools to monitor therapeutic
progress and success [11–14]. Even after SVR, re-infection
can occur in up to 10–15% of patients, especially in high-
risk populations such as injection drug users [15–17].
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Post-transplantation graft re-infection is also a critical
issue given that most liver explants (67%) remain HCV
RNA positive in the liver despite undetectable blood HCV
RNA [18]. In these clinical scenarios, a prophylactic
vaccine is likely to be an effective option. Although HCV
vaccine development is challenging due to the high viral
genetic variability, promising progress has been made to
date [16]. Thus, complementary antiviral approaches in-
cluding improved and more accessible therapies as well as
the development of a prophylactic vaccine will be neces-
sary to achieve impactful global control of infection that
leads to HCV eradication, namely a reduction of regional
incidence close to zero.
Effect of HCV cure on HCC development
HCV-induced progressive liver fibrosis and aging are
well-established high-risk conditions for HCC develop-
ment (Fig. 1) [1]. Of note, the highly carcinogenic “field
effect” in fibrotic/cirrhotic livers leads to repeated
recurrence of de novo HCC tumors even after curative
treatment of the initial primary tumors. The effect of
achieving an SVR on HCC risk has been reported in
multiple retrospective cohorts of patients who were
mostly treated with interferon-based therapies (Table 1);
these studies consistently showed significant reduction
of HCC incidence in SVR patients. A pooled analysis of
12 observational studies with a total of 25,497 patients
showed that interferon-induced SVR resulted in an ap-
proximately four-fold reduction of HCC risk irrespective
of liver disease stage (hazard ratio, 0.24; P < 0.001) [19].
Annual HCC incidence in patients with advanced liver
fibrosis or cirrhosis and active HCV infection is reported
to range from 1% to 8% [1], reducing to 0.07% to 1.2%
after achieving an SVR by interferon-based therapies
(Table 1). SVR is also implicated in reduction of all-
cause mortality, which may alter patient prognosis to the
level of the general population, although this is yet to be
established [20, 21]. In cirrhotic patients who failed to
achieve SVR, subsequent maintenance low-dose inter-
feron treatment reduced annual HCC incidence to 1.2%
when compared to 4.0% in untreated patients (hazard
ratio, 0.45; P = 0.01) [22]. This result suggests that the
anti-inflammatory and/or immunomodulatory effects of
interferon may have HCC-preventive effects irrespective
of HCV presence, although the adverse effects (flu-like
symptoms, neuropsychiatric and myelosuppressive
effects) hamper its wider use [1]. DAAs are shown to be
less toxic, and are expected to overcome the limitations
of interferon-based therapies. DAAs were indeed well-
tolerated even in compensated and decompensated
cirrhosis patients in recent clinical trials [23, 24]. How-
ever, their HCC preventive effect is still only partially
understood.
Projected trend of HCV HCC incidence with new
generation anti-HCV therapies
HCC is the most rapidly increasing cause of cancer
death, with HCV as the major etiology affecting
Fig. 1 Natural history of HCV-related HCC development and modulation by anti-HCV therapies. Progressive liver fibrosis along with aging gradually
increases the risk of hepatocarcinogenesis, which could be further accelerated by several host and viral risk factors. Annual incidences of HCC
development and recurrence after DAA-based SVR were estimated from retrospective and prospective studies summarized in Table 1. SVR induced by
interferon- or DAA-based anti-HCV therapies may result in distinct post-SVR HCC risk. AFP alpha-fetoprotein, DAA direct-acting antiviral, HCV hepatitis C
virus, HCC hepatocellular carcinoma, SVR sustained virologic response
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generally more than half of HCC patients in developed
countries such as the USA [25]. HCV incidence
increases are more prominent in specific subpopulations
such as the 1945–1965 birth cohort (baby boomers) in
the USA, in whom a 64% incidence was observed between
2003 and 2011; such an incidence is estimated to re-
sult in more than one million HCV-related cirrhosis
and/or HCC by 2020, with increasing HCC incidence
until 2030 [26–28]. In US veterans, HCC incidence
has increased by 2.5-fold and mortality has tripled
since 2001, driven overwhelmingly by HCV [29]. In a
regional population in Australia, in contrast to the
decreased incidence of hepatitis B virus (HBV)-related
HCC due to clinical implementation of the antivirals,
anti-HCV therapies had no impact on HCV-related
HCC risk between 2000 and 2014 [30]. Despite the
anticipated improvement in SVR rate with wider use
of DAAs, model-based simulation studies have pre-
dicted further increases of HCC incidence over the
next decade – even with SVR rates of 80–90% by
DAAs, predicted HCC incidence will continue to in-
crease until 2035 unless the current annual treatment
uptake rate (1–3%) is increased by more than five-
fold by 2018 [9, 31, 32]. These studies clearly highlight
the urgent need for identification of undiagnosed HCV in-
fection by implementing HCV screening programs target-
ing high-risk populations as well as improved access to
new generation anti-HCV therapies with reduced costs
and streamlined treatment intake and follow-up [33].
Post-SVR HCC risk factors
It is noteworthy that SVR does not necessarily mean elimin-
ation of HCC risk despite the substantially decreased inci-
dence. In fact, HCC can occur even more than 10 years
after successful HCV clearance (Table 1). The annual post-
SVR HCC incidence of approximately 1% is still higher than
the cancerous conditions in other organs, and the volume of
HCC-developing patients will remain substantial given the
vast size of the HCV-infected population [1].
Retrospective interrogation of previously treated
patients mostly by interferon-based regimens revealed
several post-SVR HCC-associated clinical variables, most
of which are known HCC risk factors in patients with
active HCV infection (Table 2). More advanced liver fi-
brosis as well as biochemical or imaging surrogates of
histological fibrosis (e.g., serum albumin, platelet count,
fibrosis-4 index, aspartate aminotransferase-to-platelet
ratio index, elastography-based liver stiffness) before
and/or after antiviral treatment are the most prominent
features associated with higher post-SVR HCC risk.
Older age, alcohol abuse, accompanying metabolic disor-
ders (especially diabetes), and persisting hepatic inflam-
mation, e.g., high aspartate aminotransferase, were also
associated with HCC risk. Serum alpha-fetoprotein levels
pre- and post-SVR have also been implicated as a risk
indicator, with relatively low cut-off values ranging from
5 to 20 ng/mL. In addition to the host factors, post-
SVR HCC-associated pre-treatment viral factors have
been identified, suggesting that HCV leads to irre-
versible changes in cellular signaling via mechanisms
such as epigenetic activation or imprinting, which
continue to drive carcinogenesis even after viral clear-
ance. A variant in genotype 1b HCV core protein,
Gln70(His70), was associated with increased HCC in-
cidence post-SVR, with a hazard ratio of 10.5, in a cohort
of 1273 interferon-treated Japanese patients [34]. Interest-
ingly, the variant can induce cancer-related transcriptional
dysregulation in an HCV-infectious cell system [35]. HCC
risk association of genotype 3 was also found in a cohort of
10,817 US veterans [36]. A further study suggested differ-
ences in molecular aberrations in HCC tumors from SVR
livers compared to tumors in livers with active HCV infec-
tion, which may represent SVR-specific mechanisms of car-
cinogenesis [37].
Current practice guidelines recommend regular
biannual HCC screening for cirrhotic patients with
active HCV infection, but it is still undetermined
whether and how post-SVR patients should be moni-
tored for future HCC development and if any of the
risk-associated variables has clinical utility [1]. Mo-
lecular hallmarks of persisting HCC risk in post-SVR
livers may serve as biomarkers to identify a subset of
patients still at risk and should be therefore moni-
tored by regular HCC screening. A pan-etiology HCC
risk-predictive gene signature in the liver, which was
shown to predict post-SVR HCC development, may
serve as a biomarker to identify a subset of SVR pa-
tients who should be regularly monitored for future
HCC [38].
Post-DAA HCC development and recurrence
Accumulating clinical experience of DAA-based treat-
ment has suggested that post-SVR HCC development
and recurrence may be more frequent compared to
interferon-based treatment (Table 2). In a small series of
HCC patients who achieved an SVR by all-oral DAAs
after HCC treatment, tumor recurrence rates of approxi-
mately 30% within 6 months were reported; these rates
are alarmingly high, however, the observation period was
short, a proper control group was lacking, and the find-
ing was not replicated in a subsequent study [39–43].
Further studies are needed to clarify whether DAAs in-
crease HCC incidence and to determine the natural his-
tory and baseline post-SVR HCC incidence according to
the type of anti-HCV therapy in each specific patient
population. Interestingly, chronic hepatitis B patients
treated with directly-acting anti-HBV drugs, entecavir or
other nucleos(t)ide analogues, showed higher HCC
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Table 2 Host and viral risk factors for post-sustained virologic response (SVR) hepatocellular carcinoma (HCC) development (summarized
from multivariable Cox regression models)




95% CI P value Reference
Host factor Fibrosis
Pre-SVR
Histological stage F2-4 562 Japan 4.8 10.7 2.2–192.1 <0.001 [53]
Histological stage, F3-4 1273 Japan 1.1 9.0 2.3–35.2 0.002 [34]
Histological stage, F3-4 1094 Japan 4.2 3.2 1.6–7.2 <0.001 [58]
Histological stage, F3-4 376 Taiwan 7.6 12.8 1.6–101.9 0.021 [56]
Histological stage, F3-4 871 Taiwan 3.4 4.0 1.5–10.7 0.007 [51]
Platelet, < 150 × 103/mm3 1056 Japan 4.7 2.8 1.1–7.2 0.04 [68]
Platelet, < 150 × 103/mm3 871 Taiwan 3.4 2.8 1.2–6.4 0.015 [51]
Platelet, < 150 × 103/mm3 1000 Europe
and Canada
5.7 1.1 1.0–1.1 0.029 [61]
Albumin, < 35 g/dL 399 Sweden 7.8 4.4 1.3–14.7 0.016 [69]
Liver cirrhosis, yes 1351 Taiwan 4.0 8.4 4.1–17.0 <0.001 [70]
Liver cirrhosis, yes 4663 Canada 5.6 3.2 1.2–9.0 – [71]
Post-SVR
FIB-4 index, high 522 Japan 7.2 1.7 1.1–2.9 0.02 [55]
APRI≥ 0.7 1351 Taiwan 4.0 2.9 1.5–5.7 0.002 [70]
Elastography liver
stiffness > 12 kPa
376 Taiwan 7.6 6.3 2.1–19.5 0.001 [56]
Liver cirrhosis, yes 10,738 USA 2.8 6.7 4.3–10.4 <0.001 [36]
Platelet,
< 130 × 103/mm3
571 Japan 9.0 3.9 1.5–10.1 0.004 [72]
Age, years ≥50 562 Japan 4.8 4.1 1.4–17.4 <0.01 [53]
≥55 571 Japan 9.0 3.6 1.4–9.6 0.009 [72]
≥60 642 Taiwan 4.4 3.7 1.3–10.2 0.012 [52]
≥60 871 Taiwan 3.4 3.8 1.7–8.4 0.001 [51]
≥60 4663 Canada 5.6 4.4 1.3–15.3 – [71]
>60 1094 Japan 4.2 3.1 1.3–6.6 0.009 [58]
>60 1056 Japan 4.7 3.1 1.3–7.4 0.01 [68]
>60 1000 Europe and Canada 5.7 9.8 1.2–77.8 0.031 [61]
≥65 1425 Japan 3.3 5.8 1.1–30.1 0.036 [54]
≥65 1351 Taiwan 4.0 2.7 1.2–6.3 0.017 [70]
≥65 10,738 USA 2.8 4.5 2.0–10.4 <0.001 [36]
Older 589 Taiwan 4.7 1.1 1.0–1.1 0.046 [73]
Sex Male 1094 Japan 4.2 12.0 2.8–50.0 <0.001 [58]
Male 4663 Canada 5.6 3.3 1.1–9.6 – [71]
Male 571 Japan 9.0 7.6 1.7–33.1 0.007 [72]
Diabetes Yes 522 Japan 7.2 2.1 1.1–4.0 0.045 [55]
Yes 376 Taiwan 7.6 4.0 1.3–12.1 0.021 [56]
Yes 399 Sweden 7.8 3.2 1.1–9.6 0.035 [69]
Yes 10,738 USA 2.8 1.9 1.2–2.9 0.005 [36]
Yes 1000 Europe
and Canada
5.7 2.3 1.0–5.3 0.057 [61]
Yes 4663 Canada 5.6 1.6 0.6–4.0 – [71]
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incidence compared to peg-interferon-treated patients,
suggesting that the difference in HCC-suppressive effect
may be a common phenomenon across different
hepatitis viruses [44].
Several studies suggested a possibly distinct difference
in host immune modulation between interferon and
DAAs. Rapid decline of HCV viral load by DAAs was ex-
perimentally or clinically associated with restored HCV-
specific, often exhausted, CD8+ T cell function, memory
T cell re-differentiation and lymphocyte deactivation, and
normalized NK cell function [45–48], all of which may in-
dicate a quick loss of anti-HCV immune responses. Inter-
estingly, reactivation of other co-infected viruses, such as
herpes virus, was observed after DAA-based anti-HCV
therapy [49], suggesting simultaneous loss of bystander
immune response to the viruses and possibly to neoplastic
cells, which may lead to higher HCC recurrence after
DAA treatment. On the other hand, complete remission
of follicular lymphoma after DAA-based therapy was re-
ported, suggesting that the influence of DAA-based SVR
on cancer may vary according to cancer types and bio-
logical/clinical contexts [50].
Conclusions
HCV-related HCC will remain a major health
problem in the coming decades despite the clinical
deployment of DAAs. Access to the new generation
antiviral therapies should be substantially improved to
achieve meaningful prognostic benefit at the popula-
tion level. The development of a vaccine remains an
important goal for global control and eradication of
infection. Post-SVR HCC is an emerging problem,
with urgent unmet needs for the clinical strategy of
early tumor detection and intervention, as well as elu-
cidation of its molecular mechanisms for therapeutic
target and biomarker discovery. Prolonged clinical ob-
servation should be further accumulated to determine
the impact of DAA-induced SVR on HCC develop-
ment and recurrence as well as on other cancer
types.
Table 2 Host and viral risk factors for post-sustained virologic response (SVR) hepatocellular carcinoma (HCC) development (summarized
from multivariable Cox regression models) (Continued)
Yes 589 Taiwan 4.7 3.8 1.4–10.1 0.008 [73]
Elixhauser
comorbidity index
Yes (≥1) 4663 Canada 5.6 2.2 1.0–5.1 – [71]
Alpha-fetoprotein,
ng/mL
Pre-SVR ≥8 562 Japan 4.8 2.6 1.2–6.1 <0.05 [53]
≥15 1351 Taiwan 4.0 1.9 1.0–3.6 0.038 [70]
≥20 871 Taiwan 3.4 3.2 1.6–6.2 0.001 [51]
Post-SVR ≥5 1425 Japan 3.3 8.1 2.7–23.9 <0.001 [54]
≥5 571 Japan 9.0 3.6 1.4–9.6 0.009 [72]
≥15 1351 Taiwan 4.0 2.3 1.0–5.3 0.043 [70]
≥10 1094 Japan 4.2 7.8 2.9–16.8 <0.001 [58]
Race/ethnicity Hispanic 10,738 USA 2.8 2.3 1.1–4.8 0.032 [36]
Alcohol abuse Yes 562 Japan 4.8 3.9 1.7–9.0 <0.01 [53]
Yes 10,738 USA 2.8 1.7 1.1–2.6 0.021 [36]
Yes 4663 Canada 5.6 1.1 0.34–3.3 – [71]
Illicit drug use Yes 4663 Canada 5.6 3.7 1.0–14.3 – [71]
AST >100 IU/L 1056 Japan 4.7 3.1 1.3–7.3 0.01 [68]
AST/ALT ratio >0.72 1000 Europe
and Canada
5.7 1.0 1.0–1.1 0.068 [61]
GGT >75 U/L 642 Taiwan 4.4 6.4 2.2–18.9 0.001 [52]
Viral factor Genotype 1b with
Gln70 (His70) variant
1273 Japan 1.1 10.5 2.9–38.2 <0.001 [34]
Genotype 3 10,738 USA 2.8 1.6 1.0–2.7 0.071 [36]
Genotype 3 4663 Canada 5.6 1.4 0.58–3.4 – [71]
All data are from interferon-based studies
APRI aspartate aminotransferase-to-platelet ratio index, ALT alanine aminotransferase, AST aspartate aminotransferase, FIB-4 fibrosis-4, GGT gamma-glutamyl
transpeptidase, HCV hepatitis C virus, HCC hepatocellular carcinoma, SVR sustained virologic response
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